BioImagene Revenue and Competitors
Estimated Revenue & Valuation
- BioImagene's estimated annual revenue is currently $14.3M per year.
- BioImagene's estimated revenue per employee is $251,000
Employee Data
- BioImagene has 57 Employees.
- BioImagene grew their employee count by -5% last year.
BioImagene's People
Name | Title | Email/Phone |
---|
BioImagene Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $20.3M | 81 | 7% | N/A | N/A |
#2 | $8.5M | 34 | 6% | N/A | N/A |
#3 | $4.5M | 18 | -10% | N/A | N/A |
#4 | $8M | 32 | -6% | N/A | N/A |
#5 | $5.3M | 21 | 0% | N/A | N/A |
#6 | $54.2M | 216 | 9% | N/A | N/A |
#7 | $12M | 48 | N/A | N/A | N/A |
#8 | $10M | 40 | 5% | N/A | N/A |
#9 | $30.1M | 120 | 22% | N/A | N/A |
#10 | $14.1M | 56 | 2% | N/A | N/A |
What Is BioImagene?
Ventana Medical Systems, Inc., a member of the Roche Group, is a world leader and innovator of tissue-based diagnostic solutions for patients worldwide. Ventana acquired BioImagene in August 2010. Through this acquisition, Ventana is uniquely positioned to deliver an end-to-end solution from automated staining to comprehensive patient reports. Digital Pathology solutions will complement and strengthen Ventana's current offering in image analysis and information management. Ventana digital pathology, powered by BioImagene, provides complete patient-focused solutions that are optimized for clinical labs worldwide. Ventana's digital pathology solutions represent the next step in improving workflow and efficiencies within pathology laboratories. Our solutions are used in academic medical centers, teaching hospitals, community hospitals, reference laboratories, and pharmaceutical and biotech companies.
keywords:N/AN/A
Total Funding
57
Number of Employees
$14.3M
Revenue (est)
-5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.2M | 57 | -17% | N/A |
#2 | $14.3M | 57 | 4% | N/A |
#3 | $7.2M | 57 | 0% | N/A |
#4 | $16.4M | 57 | 4% | $16.3M |
#5 | $7.6M | 58 | 29% | N/A |